Beryl Drugs Receives 'Hold' Rating from MarketsMOJO, Shows Strong Short-Term Performance but Long-Term Concerns Remain

Beryl Drugs, a microcap pharmaceutical company, has recently received a 'Hold' rating from MarketsMOJO on April 5, 2024. This upgrade is based on various technical factors, such as the stock being in a bullish range and improvements in the technical trend. The company also has a strong ROCE of 14 and is currently trading at a discount compared to its historical valuations.
Over the past year, Beryl Drugs has generated a return of 186.48%, while its profits have increased by 94%. This has resulted in a PEG ratio of 0, indicating an attractive valuation for the company. The majority of the company's shareholders are non-institutional investors.

However, Beryl Drugs has shown weak long-term fundamental strength with an average ROCE of 5.27%. Its net sales have only grown at an annual rate of 14.92% and operating profit at 0.44% over the last 5 years. The company also has a high debt to EBITDA ratio of 3.04 times, indicating a low ability to service debt.

In the latest quarter, Beryl Drugs reported flat results with a decline in net sales of -6.47%. This could be a cause for concern for investors. Overall, while the stock has shown strong performance in the past year, its long-term growth and debt management may be areas of concern. Investors are advised to hold onto their positions for now and monitor the company's performance closely.